Artivion, Inc. engages in the manufacture, processing, and distribution of medical devices and implantable human tissues used in cardiac and vascular surgical procedures for patients with aortic disease. The company is headquartered in Kennesaw, Georgia and currently employs 1,800 full-time employees. The firm operates through two segments, which include Medical Devices and Preservation Services. The medical devices and preservation services are primarily used by cardiac and vascular surgeons to treat patients with aortic disease, including heart valve disease, aortic aneurysms, and dissections, and, to a lesser extent, other conditions in cardiac and vascular surgery. The company has four product families: aortic stent grafts, On-X mechanical heart valves and related surgical products, surgical sealants, and implantable cardiac and vascular human tissues. Its aortic stent grafts include aortic arch stent grafts, abdominal stent grafts, and synthetic vascular grafts. Its surgical sealants include BioGlue Surgical Adhesive products.
How did AORT's recent EPS compare to expectations?
The most recent EPS for Artivion Inc is $0.05, not beating expectations of $0.08.
How did Artivion Inc AORT's revenue perform in the last quarter?
Artivion Inc revenue for the last quarter is $0.05
What is the revenue estimate for Artivion Inc?
According to 9 of Wall street analyst, the revenue estimate of Artivion Inc range from $132.19M to $119.27M
What's the earning quality score for Artivion Inc?
Artivion Inc has a earning quality score of B+/57.86774. The score is based on a four dimension of Profitability, Growth, Cash generation & Capital Allocation, and Leverage.
When does Artivion Inc report earnings?
Artivion Inc next earnings report is expected in 2026-05-13
What are Artivion Inc's expected earnings?
Artivion Inc expected earnings is $118.74M, according to wall-street analysts.
Did Artivion Inc beat earnings expectations?
Artivion Inc recent earnings of $115.99M does not beat expectations.